ALAMEDA, Calif., Oct. 30, 2007 (PRIME NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company innovating therapies for the treatment of chronic neurological conditions, announced today that President and CEO Kenneth Chahine, Ph.D., J.D., will present information on Avigen's development programs and product pipeline at two upcoming healthcare conferences:
